Vertex Pharmaceuticals (VRTX) Tax Provisions (2011 - 2026)

Vertex Pharmaceuticals' Tax Provisions history runs 16 years deep, the most recent figure standing at $221.5 million for Q1 2026.

• On a quarterly basis, Tax Provisions rose 163.38% year-over-year to $221.5 million in Q1 2026; TTM through Mar 2026 was $827.4 million, a 20.14% increase from a year earlier, with the FY2025 full-year figure at $690.0 million, down 12.0% from the prior year.
• Tax Provisions rose to $221.5 million in Q1 2026 per VRTX's latest filing, from $139.9 million in the prior quarter.
• Across five years, Tax Provisions topped out at $257.9 million in Q4 2022 and bottomed at $84.1 million in Q1 2025.
• The 5-year median for Tax Provisions is $202.4 million (2024), against an average of $198.0 million.
• Across the five-year window, Tax Provisions jumped 292.36% in 2022 and sank 53.15% in 2025, its largest moves.
• Year by year, Tax Provisions stood at $257.9 million in 2022, then sank by 30.67% to $178.8 million in 2023, then grew by 25.0% to $223.5 million in 2024, then sank by 37.4% to $139.9 million in 2025, then soared by 58.33% to $221.5 million in 2026.
• Per Business Quant, the three latest VRTX Tax Provisions figures stand at $221.5 million (Q1 2026), $139.9 million (Q4 2025), and $215.9 million (Q3 2025).